BACKGROUND/ OBJECTIVES: This postmarketing surveillance study assessed the preference, satisfaction, usability, and tolerability of subcutaneous self-administration of a high-concentration (50 mg/ml) ready-to-use formulation of methotrexate (MTX) in patients with rheumatoid arthritis or psoriatic arthritis. METHODS: The study enrolled 403 patients with rheumatoid or psoriatic arthritis. The first injection was administered by the attending physician or nurse, followed by five self-administered injections at weekly intervals. The high-concentration formulation consisted of a prefilled syringe with MTX 50 mg/ml solution and a pre-attached needle. Questionnaires were used to document outcomes. RESULTS: The overall assessment was 'very good' and 'good' in 87.6% of the patients and in 92.8% of the physicians/study nurses. Availability and use of a pre-attached needle was considered as very advantageous and advantageous by 91.8% of the patients and 88.8% of the physicians/study nurses. A total of 96% of the patients described the feeling of the injection as comfortable or tolerable. Patients reported that self-administration led to a feeling of more independence (89.1%) and an improved quality of life (83.6%). A total of 109 patients reported previous self-administration of low-concentration MTX formulations; 94.5% of them stated that they would prefer the high-concentration MTX formulation in the future. The formulation was generally well tolerated. Physicians' expectations concerning the benefit of switching to MTX self-administration was met in 92.8% of the patients. A total of 96.3% of the patients were considered suitable for subcutaneous self-administration of the MTX formulation. CONCLUSIONS: The 50 mg/ml prefilled syringe appears to be a valuable treatment option for patients with rheumatoid and psoriatic arthritis in need of MTX. This is supported by the strong appreciation of the patients as well as their attending healthcare professionals for its convenience and tolerability. The results confirm the findings and experience from a clinical study performed in Germany in 2009, which showed that 93% of the patients prefer the 50 mg/ml prefilled syringe with a pre-attached needle.
BACKGROUND/ OBJECTIVES: This postmarketing surveillance study assessed the preference, satisfaction, usability, and tolerability of subcutaneous self-administration of a high-concentration (50 mg/ml) ready-to-use formulation of methotrexate (MTX) in patients with rheumatoid arthritis or psoriatic arthritis. METHODS: The study enrolled 403 patients with rheumatoid or psoriatic arthritis. The first injection was administered by the attending physician or nurse, followed by five self-administered injections at weekly intervals. The high-concentration formulation consisted of a prefilled syringe with MTX 50 mg/ml solution and a pre-attached needle. Questionnaires were used to document outcomes. RESULTS: The overall assessment was 'very good' and 'good' in 87.6% of the patients and in 92.8% of the physicians/study nurses. Availability and use of a pre-attached needle was considered as very advantageous and advantageous by 91.8% of the patients and 88.8% of the physicians/study nurses. A total of 96% of the patients described the feeling of the injection as comfortable or tolerable. Patients reported that self-administration led to a feeling of more independence (89.1%) and an improved quality of life (83.6%). A total of 109 patients reported previous self-administration of low-concentration MTX formulations; 94.5% of them stated that they would prefer the high-concentration MTX formulation in the future. The formulation was generally well tolerated. Physicians' expectations concerning the benefit of switching to MTX self-administration was met in 92.8% of the patients. A total of 96.3% of the patients were considered suitable for subcutaneous self-administration of the MTX formulation. CONCLUSIONS: The 50 mg/ml prefilled syringe appears to be a valuable treatment option for patients with rheumatoid and psoriatic arthritis in need of MTX. This is supported by the strong appreciation of the patients as well as their attending healthcare professionals for its convenience and tolerability. The results confirm the findings and experience from a clinical study performed in Germany in 2009, which showed that 93% of the patients prefer the 50 mg/ml prefilled syringe with a pre-attached needle.
Authors: Stephan Pavy; Arnaud Constantin; Thao Pham; Laure Gossec; Jean-Francis Maillefert; Alain Cantagrel; Bernard Combe; René-Marc Flipo; Philippe Goupille; Xavier Le Loët; Xavier Mariette; Xavier Puéchal; Thierry Schaeverbeke; Jean Sibilia; Jacques Tebib; Daniel Wendling; Maxime Dougados Journal: Joint Bone Spine Date: 2006-03-23 Impact factor: 4.929
Authors: F M Balis; J Mirro; G H Reaman; W E Evans; C McCully; K M Doherty; R F Murphy; S Jeffries; D G Poplack Journal: J Clin Oncol Date: 1988-12 Impact factor: 44.544
Authors: Ulf Müller-Ladner; Karin Rockwitz; Jan Brandt-Jürgens; Roland Haux; Peter Kästner; Jürgen Braun; Winfried Demary; Cécile Guimbal-Schmolck; Uwe Pichlmeier; Andreas Brandt Journal: Open Rheumatol J Date: 2010-03-18
Authors: J Braun; P Kästner; P Flaxenberg; J Währisch; P Hanke; W Demary; U von Hinüber; K Rockwitz; W Heitz; U Pichlmeier; C Guimbal-Schmolck; A Brandt Journal: Arthritis Rheum Date: 2008-01
Authors: Sophie De Mits; Jan Lenaerts; Bert Vander Cruyssen; Herman Mielants; René Westhovens; Patrick Durez; Dirk Elewaut Journal: PLoS One Date: 2016-11-28 Impact factor: 3.240
Authors: Heather L Gelhorn; Zaneta Balantac; Christopher S Ambrose; Yen N Chung; Brian Stone Journal: Patient Prefer Adherence Date: 2019-07-25 Impact factor: 2.711
Authors: Elena Generali; Greta Carrara; Alessandra Bortoluzzi; Maria De Santis; Angela Ceribelli; Carlo A Scirè; Carlo Selmi Journal: J Transl Autoimmun Date: 2021-08-16